Advertisement

Topics

Companies Related to "Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors" [Most Relevant Company Matches] RSS

01:59 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors" found in our extensive corporate database of over 50,000 company records.

Showing "Monoclonal Antibody Therapy Treating Patients With Advanced Solid" Companies 1–25 of 7,300+

Extremely Relevant

KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc., a U.S. based, private monoclonal company, uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. The company has multiple programs that have been in seven Phase 1 or 2 clinical trials in the last few years. KB001 is a PEGylated monoclonal antibody fragmen...


A&G Pharmaceutical Incorporated

A&G Pharmaceutical, Inc. (A&G) was incorporated in Delaware on June 6, 2000, as a "C" Corporation, to make use of two proprietary technologies that are unique to the Company. A&G is located in Baltimore, Maryland, and consists of two distinct but integrate divisions: 1) the Pharmaceutical Division and 2) the Monoclonal Antibody Services Division. Pharmaceutical Division Breast cancer is the most ...

Abnova Corporation

Abnova is the world largest monoclonal antibody manufacturer. We have a capacity of generating 500 mouse monoclonal antibodies per month. Rather than the traditional method of monoclonal antibody production, Abnova is taking a genomic/proteomic approach for the antibody development. Our goal is to have at least one antibody to every human expressed gene in human genome. We manufacture all our prod...


Abnova Corporation

Abnova is the world largest monoclonal antibody manufacturer. We have a capacity of generating 500 mouse monoclonal antibodies per month. Rather than the traditional method of monoclonal antibody production, Abnova is taking a genomic/proteomic approach for the antibody development. Our goal is to have at least one antibody to every human expressed gene in human genome. We manufacture all our prod...

Antibodies by Design

Antibodies by Design uses proven MorphoSys recombinant antibody technology to provide high quality monoclonal antibodies to its customers in record time. The HuCAL GOLD® library contains over 15 billion unique human antibody genes in Fab format. This wealth and diversity of sequences is coupled with proprietary automated screening techniques and advanced data management systems to quickly identif...

Relevant

Trellis Bioscience

Monoclonal antibody technology was the research breakthrough of the 1980’s. With the discovery by Milstein and Kohler in Cambridge, England, Hybritech became the first company dedicated to the production of monoclonal antibodies, commercializing the first diagnostic tests and leading to two subsequent companies that furthered monoclonal antibody development, GenProbe and IDEC. The use of monoclo...

Arsanis Inc

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The company’s major focus is on life threatening infections that are caused by antibiotic resistant pathogens, occur in immune compromised patients or are associated with ...

Arsanis, Inc

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated wit...

Arsanis Biosciences GmbH

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that are caused by antibiotic resistant pathogens, occur in immune compromised patients or are associated with ...

Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (“OMT”) is a private biotechnology company with a new, fully human monoclonal antibody platform based on transgenic rats. The rat is a widely used laboratory animal with a well characterized immune system, a nearly complete genome sequence, and established transgenesis and hybridoma technologies. OMT’s antibody ...

Arsanis, Inc.

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated wit...

Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong financial foundations, good medium term prospects and significant opportunities for growth in the longer term.

Lpath

Lpath, Inc., headquartered in San Diego, California, is a theranostics company focused on bioactive signaling lipids as targets for treating and diagnosing important human diseases. Lpath's lead product candidate, Sphingomab™, is a monoclonal antibody (mAb) against a validated cancer target, sphingosine-1-phosphate (S1P), and has demonstrated compelling results against six different forms of sol...

OncoResponse

OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. Our most advanced program, ONCR-201 is an anti-EMP2 fully-human monoclonal antibody being developed for female malignancies. The OncoResponse discovery engine is working to increase the success rate of cancer immunotherapies by ident...

Grid Therapeutics, LLC

Grid Therapeutics is a biotech company based on the innovative platform for discovering and isolating human derived antibodies. Dr Edward F. Patz, Jr, is the co-founder and CEO of Grid, located in Durham, North Carolina. The lead antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. ...

Solid GT

Solid GT, a subsidiary of Solid Biosciences, is a gene therapy platform focused on developing novel, disease-modifying therapeutics for Duchenne muscular dystrophy. The company’s licensed technology has demonstrated efficacy in various DMD animal models and lead candidates are currently undergoing IND-enabling studies. Founded in 2014, Solid GT is col...

Epitomics, Inc.

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics, Inc...

Mathison Immuno Scientific Incorporated

CUSTOM MONOCLONAL ANTIBODY SERVICE Difficult epitopes are our specialty. Antibody available in culture supernatant or ascites. Antibody purified to your specific requirements Competitive prices & Stepwise payment plan Confidentiality guarantee

f-star

F-star is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab™ antibody fragments, and bispecific antibodies, by modifying th...

InNexus Biotechnology, Inc.

approaches that add secondary properties to monoclonal antibodies (binding is a primary property) and applies to virtually every antibody product currently in development. Adding these secondary properties can increase the potency of antibodies or add new properties such as the ability to penetrate into living cells.As an example, InNexus utilized SAT with a humanized monoclonal antibody, licensed...

AgriSera AB

AgriSera is a privately owned Swedish company that provides complete polyclonal and monoclonal antibody production services. Since 1980 we have developed a range of reliable, high-quality antibody production and purification methods. Our main aim is to assist our customers during the complete process of antibody production and to offer continuous support during further antibody characterisation.

Corixa Corporation

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune disease, cancer and infectious disease by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis...

Genetronics Biomedical

Genetronics' most advanced effort involves treating those with head and neck cancer, a particularly devastating cancer that can severely limit the ability of these patients to see, taste, hear, talk, breathe, or swallow. Genetronics received approval from the U.S. Food and Drug Administration and initiated Phase II multi-center clinical trials at nine sites in the U.S. The trials test the effectiv...

Immunomedics, Inc.

Immunomedics (the “Company”) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled ...

Cytogen

Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of cancer patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets QUADRAMET® (samarium Sm-153 lexidronam injection), PROSTASCINT® (capromab pendetide), and SOLTAMOX™ (tamoxifen citrate) to the U.S. oncology market. Q...


More From BioPortfolio on "Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks